


SYSTEMATIC REVIEWS WITH META-ANALYSES IN HEALTH RESEARCH

Nils Runge



CONTENT

- 1. Initial considerations
- 2. Components of Systematic Reviews
- 3. Meta-Analyses
- 4. The Forest Plot



INITIAL CONSIDERATIONS




WHAT IS A SYSTEMATIC REVIEW?

"A systematic review attempts to identify, appraise and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a specific research question."

"Researchers conducting systematic reviews use **explicit**, **systematic methods** that are selected with a view aimed at **minimizing bias**, to produce more reliable findings to **inform decision making**."



WHY ARE SYSTEMATIC REVIEWS RELEVANT?




https://s4be.cochrane.org/blog/2014/04/29/th e-evidence-based-medicine-pyramid/



WHY ARE SYSTEMATIC REVIEWS RELEVANT?

- Comprehensive Analysis
- Identifying Research Gaps (or the lack of gaps)
- Synthesizing Conflicting Evidence
- Quality Assessment
- Transparency and Reproducibility
- Evidence-Based Decision Making (Policy and Practice Impact)



https://s4be.cochrane.org/blog/2014/04/29/the-evidence-based-medicine-pyramid/



TYPES OF REVIEWS

SYSTEMATIC, SCOPING AND NARRATIVE REVIEWS

	Systematic Review	Scoping Review	Narrative Review
Purpose	To systematically synthesize and analyze all available evidence on a specific research question or topic.	To map and summarize existing literature, often to identify gaps in research or clarify concepts.	To provide a (comprehensive) overview of a topic by synthesizing evidence and expert opinions in a narrative form.
Research Question	Typically focused on specific question	May have broader research questions and aims	Often very general
Methodology	Rigorous and structured methodology	Less stringent methodology (?) but still systematic	No strict methodology



TYPES OF REVIEWS

SYSTEMATIC, SCOPING AND NARRATIVE REVIEWS

	Systematic Review	Scoping Review	Narrative Review
Synthesis of Evidence	Quantitative synthesis (meta-analysis) or qualitative synthesis	Focus on summarizing and mapping the literature	Relies on narrative synthesis
Reporting Standards	Adheres to established reporting guidelines such as PRISMA	Adheres to established reporting guidelines such as PRISMA	Reporting standards vary
Impact and Use	Often used to inform evidence-based practice, policy-making, and further research.	Identifies gaps in literature, informs research priorities (e.g. for systematic reviews).	Provides a broad overview of a topic (often for other researchers or clinicians)



SYSTEMATIC REVIEW AND META-ANALYSES

"If the results of the **individual studies are combined** to produce an overall **statistic**, this is usually called a meta-analysis"



SYSTEMATIC REVIEW AND META-ANALYSES

"If the results of the **individual studies are combined** to produce an overall **statistic**, this is usually called a meta-analysis"

"Not every systematic review contains a meta-analysis. **This might not be appropriate** if the designs of the studies are too different, if the outcomes measured are not sufficiently similar, or if there are concerns about the quality of the studies, for an average result across the studies to be meaningful."






SYSTEMATIC REVIEW AND META-ANALYSES

"If the results of the **individual studies are combined** to produce an overall **statistic**, this is usually called a meta-analysis"


"Not every systematic review contains a meta-analysis. **This might not be appropriate** if the designs of the studies are too different, if the outcomes measured are not sufficiently similar, or if there are concerns about the quality of the studies, for an average result across the studies to be meaningful."





IMPORTANT RESOURCES

Cochrane Handbook



https://training.cochrane.org/handbook



IMPORTANT RESOURCES

PRISMA guidelines



https://www.prisma-statement.org/



Online learning

Trusted evidence. Informed decisions. Better health. Contact | Cochrane.org |
Search...

Cochrane Handbook for Systematic Reviews of Interventions

Guides and handbooks

Search Handbook Q

Version 6.4, 2023

Learning events

Overview

 Part 1: About Cochrane Reviews Senior Editors: Julian Higgins¹, James Thomas²
Associate Editors: Jacqueline Chandler³, Miranda Cumpston^{4,5}, Tianjing Li⁶, Matthew Page⁴. Viv

Trainers' Hub



IMPORTANT RESOURCES

PROSPERO



https://www.crd.york.ac.uk/prospero/




BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n71 (Published 29 March 2021) Cite this as: BMJ 2021;372:n71



Overview

Part 1: About Cochrane Reviews

PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews



Senior Editors: Julian Higgins¹, James Thomas²



Associate Editors: Jacqueline Chandler³, Miranda Cumpston^{4,5}, Tianjing Li⁶, Matthew Page⁴, Viv





RESEARCH QUESTION

PICO(S)

Population – Intervention – Comparator – Outcome – (Setting/Study design)

What is the effectiveness of *CBT-I* compared to *inactive control* on *pain* in *patients* with comorbid insomnia and chronic non-cancer pain (in a community setting)?



RESEARCH QUESTION

PEO(S)

Population – Exposure – Outcome – (Study design/Setting)


Are sleep problems/disorders at baseline associated with an increased risk for the development of chronic musculoskeletal pain in people without pain at baseline?



PREVIOUS REVIEWS AND PROTOCOLS



PROSPERO



PubMed



COMPONENTS OF SYSTEMATIC REVIEWS ELIGIBILITY CRITERIA


- Based on research question (PICO/PEO)
- As specific as possible for all components of PICO
 - How to define the **population** (E.g. people with insomnia and chronic pain?)
 - What counts as the intervention (E.g How is CBT-I defined?)
 - Which control interventions are allowed? (E.g. only waitlist or also active controls like medication)
 - Which outcomes and how were they measured? (E.g. pain)
 - Other aspects like language, study type...
- Need to be pre-registered!



COMPONENTS OF SYSTEMATIC REVIEWS PROTOCOL PRE-REGISTRATION

Why pre-registration?

- Helps planning
- Reduces publication bias/waste
- Increases transparency
- Increases review quality (e.g. reporting bias)
- Part of PRISMA
- Eases publication of paper





PROTOCOL PRE-REGISTRATION

What should I pre-register?

- Follow the PROSPERO form (use it to check your preparations)
- More detail is better

Can I make any changes afterwards?

- Yes. But be open about it.
- Consider sensitivity analyses





COMPONENTS OF SYSTEMATIC REVIEWS SYSTEMATIC SEARCH (1)


Which databases should I search?

- MEDLINE (via pubmed)
- EMBASE
- Cochrane Central
- PsycInfo
- (depending on research field)
- Grey literature and protocols (Think publication bias)



SYSTEMATIC SEARCH (2)

Boolean Logic



https://historyinformationliteracy.wordpress.com/class-1-boolean-logic-and-searching/



SYSTEMATIC SEARCH (3)

Boolean Logic - OR

P – "Chronic pain" **OR** Pain **OR** "persistent pain"

I – CBT-I **OR** "Cognitive behavioural therapy for insomnia" **OR** "Cognitive behavioral therapy for insomnia"

• • •



SYSTEMATIC SEARCH (3)

Boolean Logic - AND

(Population terms with OR)

AND (Intervention terms with OR)

AND (Comparator terms with OR)

AND (Outcome terms with OR)



COMPONENTS OF SYSTEMATIC REVIEWS STUDY SELECTION (1)

Duplicate exclusion

Titles

Abstracts


Full-texts

Two independent researchers

https://blogs.lshtm.ac.uk/library/2018/12/07/removing-duplicates-from-an-endnote-library/



STUDY SELECTION (2)




https://rayyan.ai/



All reviews

Rating |

STUDY SELECTION (3)



Runge et al. 2023



COMPONENTS OF SYSTEMATIC REVIEWS DATA EXTRACTION

- Standardized data extraction sheets
- Two independent reviewers
- Extract all relevant study and statistical data
- Contact authors for missing/unclear data



RISK OF BIAS ASSESSMENT

- Assessment on outcome level rather than study level
- Different tools for different study types
- Different domains (Cochrane RoB tool 2):
 - Bias arising from the randomization process
 - Bias due to deviations from intended interventions
 - Bias due to missing outcome data
 - Bias in measurement of the outcome
 - Bias in selection of the reported result

Sterne et al.2019



RISK OF BIAS ASSESSMENT

Study ID	<u>Outcome</u>	<u>D1</u>	<u>D2</u>	<u>D3</u>	<u>D4</u>	<u>D5</u>	<u>Overall</u>		
Azeez 2020	GFI	1		-	1	1		•	Low risk
Bachmair 2022	FSS	+	+	1	!	+	!	!	Some concerns
Bachmair 2022	CFS	+	+	!	1	+	!		High risk
Bestas 2022	PSQI	!	+	•	!	!	!	D1	Randomisation process
Bestas 2022	FSS	!	•	+	!	!	!	D2	Deviations from the intended interventions
Bilberg 2005	SF-36 Vitality	!	!	•	!	!	!	D3	Missing outcome data
Casilda-Lopez 2017	VAS Fatigue	+	+	+	!			D4	Measurement of the outcome
Cheung 2014	PSQI	•	+	+	!	•	!	D5	Selection of the reported result

Runge et al. 2023



COMPONENTS OF SYSTEMATIC REVIEWS DATA SYNTHESIS (QUALITATIVE)

- Descriptive summary of included studies
- Consider:
 - PICO domains
 - Used methods
 - Funding sources
 - Results within the paper
 - •



META-ANALYSIS (OF CONTINUOUS OUTCOMES)





META-ANALYSIS

DOES A META-ANALYSIS MAKE SENSE?

Check for comparability in context of:

- Population
- Intervention
- Comparison
- Outcome
- ... based on qualitative synthesis







META-ANALYSIS

INVERSE-VARIANCE APPROACH TO META-ANALYSIS

- Weight given to each study is chosen to be the inverse of the variance of the effect estimate
 - i.e. 1 over the square of its standard error
 - Larger studies (smaller standard errors) are given more weight than smaller studies (larger standard errors)
- Using weighted effect sizes from each study, an overall effect size estimate is computed (weighted average)
- The standard error of the summary intervention effect can be used to derive a confidence interval (Information about precision of result)



META-ANALYSIS

FIXED-EFFECTS META-ANALYSIS

Assumptions:

- Any variation observed between the studies is due to random sampling error, and all other sources of variation are negligible.
- The fixed-effects model is appropriate when the studies being combined are <u>considered to be sampling from the same</u> <u>population and have similar methodologies and characteristics</u>



FIXED-EFFECTS META-ANALYSIS

Interpretation:

• There is <u>one</u> true effect size that underlies all the studies being analyzed.





RANDOM-EFFECTS META-ANALYSIS

Assumptions:

- Observed variation between studies is not just due to random sampling error <u>but also includes genuine differences in effect sizes</u> <u>between studies.</u>
- This model is appropriate when the studies being combined are not identical:
 - They are drawn from populations with different effect sizes
 - OR There is heterogeneity among the studies in terms of methodology, participant characteristics, or other factors



RANDOM-EFFECTS META-ANALYSIS – STATISTICALLY SPEAKING

- In the random-effects model, both the within-study variance and the between-study variance are estimated from the data.
- The <u>within-study variance</u> reflects the variability of effect sizes within each individual study – random/sampling error
- The <u>between-study variance</u> quantifies the variability of true effect sizes (genuine differences) across all included studies.



RANDOM-EFFECTS META-ANALYSIS

Interpretation:

 The result is the best estimate of the average treatment effect.





CONSIDER: HARTUNG-KNAPP METHOD

Problem:

- The standard (DerSimonian-Laird) randomeffects method tends to produce overly narrow confidence intervals
 - This may overstate the precision of the overall effect estimate, especially in small samples



CONSIDER: HARTUNG-KNAPP METHOD

Solution:

- The Hartung-Knapp method adjusts for this bias by penalizing the precision of the estimated variance
 - Gives less weight to studies with overly precise estimates
 - This leads to wider and more conservative confidence intervals.



MEAN DIFFERENCE VERSUS STANDARDIZED MEAN DIFFERENCE

- Meta-analyses with the <u>same</u> outcome measure and scaling
 - Use mean difference as measure of effect
- Meta-analyses with <u>different</u> outcome measures and/or scaling
 - Use standardized mean differences (SMD) as measure of effect



META-ANALYSIS MEAN DIFFERENCE

- Meta-analyses with the same outcome measure and scaling
 - Interpretation on the scaling of the outcome measure
 - Consider clinical relevance



STANDARDIZED MEAN DIFFERENCE

- Meta-analyses with different outcome measures and/or scaling
 - SMD = (Mean of Group 1 Mean of Group 2) / Pooled Standard Deviation
 - The pooled standard deviation = weighted average of the standard deviations of both groups



STANDARDIZED MEAN DIFFERENCE

Interpretation of SMD

- The resulting SMD represents the difference between the means of the two groups
 -> Expressed in standard deviation units.
- Cohen's d/hedges g are commonly used metrics for interpreting the magnitude of the SMD:


Small effect size: SMD 0.2- 0.5

Medium effect size: SMD 0.5 – 0.8

Large effect size: SMD >0.8



THE FOREST PLOT





THE FOREST PLOT

OVERVIEW

	EPA pro	ogram		С	ontrol			Std. Mean Difference	Std. Mean Difference
Study	Mean	_		Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Loeppenthin 2022 [65]	-9.36	7.71	17	1.72	8.22	21	5.4%	-1.39 [-2.10; -0.67]	
Durcan 2014 [61]	-11.20	11.40	40	-0.10	16.15	38	9.7%	-0.80 [-1.26; -0.34]	
Evans 2013 [62]	-17.00	17.31	11	-1.00	22.22	15	4.5%	-0.79 [-1.60; 0.02]	
Bilberg 2005 [60]	-12.10	17.60	20	1.60	18.80	23	6.7%	-0.75 [-1.37; -0.13]	
McKenna 2021 [67]	-10.55	17.81	10	2.65	28.16	8	3.4%	-0.58 [-1.53; 0.38]	
Garcia-Morales 2020b [63]] -13.39	19.54	36	-1.31	27.09	27	8.7%	-0.52 [-1.03; -0.02]	- = -
Garcia-Morales 2020a [63]] -12.79	27.86	32	0.85	24.33	35	9.1%	-0.52 [-1.01; -0.04]	- =
Katz 2017 [64]	-4.80	7.70	31	-1.60	8.10	26	8.3%	-0.41 [-0.93; 0.12]	-
Li 2020 [66]	-0.30	1.35	39	0.10	1.35	41	10.2%	-0.30 [-0.74; 0.14]	
Puksic 2021 [72]	-6.42	19.92	24	-2.07	15.61	24	7.5%	-0.24 [-0.81; 0.32]	- -
Neuberger 2007 [68]	-2.54	10.75	141	-1.00	10.57	68	14.6%	-0.14 [-0.43; 0.15]	
Azeez 2020 [59]	-0.60	9.87	24	0.16	12.49	21	7.2%	-0.07 [-0.65; 0.52]	: •
Ward 2018 [70]	-0.80	3.04	13	-1.57	3.00	12	4.7%	0.25 [-0.53; 1.04]	 •
Total (95% CI)			438			359	100.0%	-0.45 [-0.64; -0.25]	•
Prediction interval Heterogeneity: Tau ² = 0.0439	9: Chi ² = :	20.22. c	if = 12 (P = 0 0	6): I ² = 4	41%	\	[-0.96; 0.06]	
	.,	, ~	(-,, .				-2 -1 0 1 2
									EPA program Control

Figure 3: Forest plot showing the results of the metaanalysis on fatigue in the short-term comparing exercise and physical activity programs with inactive control in people with rheumatoid arthritis



THE FOREST PLOT INTERPRETATION

- Statistically significant result if Diamond (95%CI) does not cross 0
- Effect size is based on SMD
- Interpretation in paper: "EPA programs <u>may</u> reduce fatigue <u>slightly</u> compared to inactive control in the short-term (SMD -0.45; 95% CI -0.64 to -0.25; I2 = 41%; Low certainty)"

	EPA pro	ogram		С	ontrol			Std. Mean Difference	Std. Mean Difference
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Loeppenthin 2022 [65]	-9.36	7.71	17	1.72	8.22	21	5.4%	-1.39 [-2.10; -0.67]	
Durcan 2014 [61]	-11.20	11.40	40	-0.10	16.15	38	9.7%	-0.80 [-1.26; -0.34]	
Evans 2013 [62]	-17.00	17.31	11	-1.00	22.22	15	4.5%	-0.79 [-1.60; 0.02]	
Bilberg 2005 [60]	-12.10	17.60	20	1.60	18.80	23	6.7%	-0.75 [-1.37; -0.13]	-
McKenna 2021 [67]	-10.55	17.81	10	2.65	28.16	8	3.4%	-0.58 [-1.53; 0.38]	
Garcia-Morales 2020b [63]	-13.39	19.54	36	-1.31	27.09	27	8.7%	-0.52 [-1.03; -0.02]	
Garcia-Morales 2020a [63]	-12.79	27.86	32	0.85	24.33	35	9.1%	-0.52 [-1.01; -0.04]	
Katz 2017 [64]	-4.80	7.70	31	-1.60	8.10	26	8.3%	-0.41 [-0.93; 0.12]	- *
Li 2020 [66]	-0.30	1.35	39	0.10	1.35	41	10.2%	-0.30 [-0.74; 0.14]	- 12 +
Puksic 2021 [72]	-6.42	19.92	24	-2.07	15.61	24	7.5%	-0.24 [-0.81; 0.32]	- -
Neuberger 2007 [68]	-2.54	10.75	141	-1.00	10.57	68	14.6%	-0.14 [-0.43; 0.15]	
Azeez 2020 [59]	-0.60	9.87	24	0.16	12.49	21	7.2%	-0.07 [-0.65; 0.52]	
Ward 2018 [70]	-0.80	3.04	13	-1.57	3.00	12	4.7%	0.25 [-0.53; 1.04]	
Total (95% CI)			438			359	100.0%	-0.45 [-0.64; -0.25]	•
Prediction interval								[-0.96; 0.06]	
Heterogeneity: Tau ² = 0.0439); Chi ² = 2	20.22, d	lf = 12 (P = 0.0	6); I ² = 4	11%			/ 1 1 1 1 1
									-2 -1 0 1
									EPA program Control



THE FOREST PLOT HETEROGENEITY

 \circ I²

 Proportion of total variation in effect sizes across studies that is due to heterogeneity rather than chance/measurement error.


	EPA pr				ontrol			Std. Mean Difference	
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Loeppenthin 2022 [65]	-9.36	7.71	17	1.72	8.22	21	5.4%	-1.39 [-2.10; -0.67]	
Durcan 2014 [61]	-11.20	11.40	40	-0.10	16.15	38	9.7%	-0.80 [-1.26; -0.34]	
Evans 2013 [62]	-17.00	17.31	11	-1.00	22.22	15	4.5%	-0.79 [-1.60; 0.02]	
Bilberg 2005 [60]	-12.10	17.60	20	1.60	18.80	23	6.7%	-0.75 [-1.37; -0.13]	
McKenna 2021 [67]	-10.55	17.81	10	2.65	28.16	8	3.4%	-0.58 [-1.53; 0.38]	
Garcia-Morales 2020b [63]	-13.39	19.54	36	-1.31	27.09	27	8.7%	-0.52 [-1.03; -0.02]	
Garcia-Morales 2020a [63]	-12.79	27.86	32	0.85	24.33	35	9.1%	-0.52 [-1.01; -0.04]	
Katz 2017 [64]	-4.80	7.70	31	-1.60	8.10	26	8.3%	-0.41 [-0.93; 0.12]	- #
Li 2020 [66]	-0.30	1.35	39	0.10	1.35	41	10.2%	-0.30 [-0.74; 0.14]	-
Puksic 2021 [72]	-6.42	19.92	24	-2.07	15.61	24	7.5%	-0.24 [-0.81; 0.32]	- -
Neuberger 2007 [68]	-2.54	10.75	141	-1.00	10.57	68	14.6%	-0.14 [-0.43; 0.15]	-
Azeez 2020 [59]	-0.60	9.87	24	0.16	12.49	21	7.2%	-0.07 [-0.65; 0.52]	
Ward 2018 [70]	-0.80	3.04	13	-1.57	3.00	12	4.7%	0.25 [-0.53; 1.04]	 •
Total (95% CI)			438			359	100.0%	-0.45 [-0.64; -0.25]	•
Prediction interval	- C1 ·2				o. 12	440/		[-0.96; 0.06]	
Heterogeneity: Tau ² = 0.0439	; Cni" = :	20.22, d	T = 12 (P = 0.0	0); 1" = 4	11%			2 1 0 1
									-2 -1 0 1
									EPA program Control



THE FO

 \circ I²

Propactacropactrath





THE FOREST PLOT HETEROGENEITY

\circ I²

 Proportion of total variation in effect sizes across studies that is due to heterogeneity rather than chance/measurement error.

Prediction interval

 The prediction interval provides a range within which we can expect a future observation (effect size) from a new study to fall.

	EPA pro	ogram		С	ontrol			Std. Mean Difference	e Std. Mean Differ	ence
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 959	% CI
Loeppenthin 2022 [65]	-9.36	7.71	17	1.72	8.22	21	5.4%	-1.39 [-2.10; -0.67]		-
Durcan 2014 [61]	-11.20	11.40	40	-0.10	16.15	38	9.7%	-0.80 [-1.26; -0.34]		
Evans 2013 [62]	-17.00	17.31	11	-1.00	22.22	15	4.5%	-0.79 [-1.60; 0.02]		
Bilberg 2005 [60]	-12.10	17.60	20	1.60	18.80	23	6.7%	-0.75 [-1.37; -0.13]		
McKenna 2021 [67]	-10.55	17.81	10	2.65	28.16	8	3.4%	-0.58 [-1.53; 0.38]		
Garcia-Morales 2020b [63]	-13.39	19.54	36	-1.31	27.09	27	8.7%	-0.52 [-1.03; -0.02]		
Garcia-Morales 2020a [63]	-12.79	27.86	32	0.85	24.33	35	9.1%	-0.52 [-1.01; -0.04]	- •	
Katz 2017 [64]	-4.80	7.70	31	-1.60	8.10	26	8.3%	-0.41 [-0.93; 0.12]	- •	
Li 2020 [66]	-0.30	1.35	39	0.10	1.35	41	10.2%	-0.30 [-0.74; 0.14]	- 11	
Puksic 2021 [72]	-6.42	19.92	24	-2.07	15.61	24	7.5%	-0.24 [-0.81; 0.32]	- - 	
Neuberger 2007 [68]	-2.54	10.75	141	-1.00	10.57	68	14.6%	-0.14 [-0.43; 0.15]		
Azeez 2020 [59]	-0.60	9.87	24	0.16	12.49	21	7.2%	-0.07 [-0.65; 0.52]		
Ward 2018 [70]	-0.80	3.04	13	-1.57	3.00	12	4.7%	0.25 [-0.53; 1.04]		_
Total (95% CI)			438			359	100.0%	-0.45 [-0.64; -0.25]	•	
Prediction interval								[-0.96; 0.06]		
Heterogeneity: Tau ² = 0.0439); Chi ² = :	20.22, d	f = 12 (P = 0.0	6); I ² = 4	11%				Т
g ,			(,.				-2 -1 0	1
									EPA program Conti	rol




THE FO

 \circ I²

Propacrc rath

Predic

The whice (effective)





THE FOREST PLOT SENSITIVITY ANALYSES

- Evaluate robustness of results by examining the effects of excluding certain studies or changing analysis methods.



THE FOREST PLOT SENSITIVITY ANALYSES

Sensitivity analysis (Result main analysis: SMD -0.45; -0.64 to -0.25, I2 = 41%)	SMD (95%CI)
Exclusion of studies with high RoB	-0.50 (-0.72 to -0.28), I ² = 46%
Use of intercorrelation coefficient of r =0.7 to estimate change standard deviations where required	-0.52 (-0.73 to -0.31), I ² = 48%
Exclusion of the study Katz et al.[9]	-0.45 (-0.65 to -0.24), I ² = 46%
Use of the original standard deviations from Durcan et al.[10]	-0.51 (-0.76 to -0.26), I ² = 62%
Use of alternative outcome measures of studies that provided data on more than one measure of fatigue	-0.42 (-0.64 to -0.21), I ² = 53%




THE FOREST PLOT SUBGROUP ANALYSES

- Investigate whether the effect size varies across different subgroups of studies or participants
- Provide insights into potential sources of heterogeneity.



THE FOREST PLOT SUBGROUP ANALYSES





GRADE

"GRADE is a systematic approach to rating the certainty of evidence in systematic reviews and other evidence syntheses"

(Cochrane 2024)

Great resource:

https://training.cochrane.org/onlinelearning/cochrane-methodology/gradeapproach/jce-series



GRADE - INTERPRETATION

Certainty level	Current definition
High	We are very confident that the true effect lies close to that of the estimate of the effect
Moderate	We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low	Our confidence in the effect estimate is limited : The true effect may be substantially different from the estimate of the effect
Very low	We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Balshem et al. 2011



GRADE - INTERPRETATION

All outcomes start with high certainty

Downgrade for:

- Study designs
- Risk of Bias (study limitations)
- Imprecision
- Inconsistency
- Indirectness
- Publication bias



GRADE - INTERPRETATION

Effect size	Certainty of evidence	Statement
Small	High	X reduces/increases outcome slightly X results in a slight reduction/increase in outcome
Small	Moderate	X probably reduces/increases outcome slightly X likely reduces/increases outcome slightly
Small	Low	X may reduce/increase outcome slightly The evidence suggests X reduces/increases outcome slightly
Small	Very low	The evidence is very uncertain about the effect of X on outcome X may reduce/increase/have little to no effect on outcome but the evidence is very uncertain
		Santesso et al. 2020



SUMMARY

SYSTEMATIC REVIEWS WITH META-ANALYSES

If done well:

- They are an important part of evidencebased medicine
- They can be a comprehensive summary of the current evidence for a specific research question
- They can be used to guide clinical practice, policy and future research



SUMMARY

SYSTEMATIC REVIEWS WITH META-ANALYSES

If done poorly or if misinterpreted:

- They can have negative influence on clinical practice/ future research/ research funding...
- They can create confusion within a field
- They can be used to prove a point
- They can undermine trust in scientific methods

